To improve the appropriateness and efficiency of diagnostic serological tests and subsequent antibiotic treatment, clinical data from 102 patients with unclassified arthritis were analysed to investigate whether the presence of positive IgG antibodies to Borrelia burgdorferi could be predicted.
12-0, for patients ranked 2 to 4, 4'5, and for patients with arthritis of the knee, 3-0. These likelihood ratios were associated with a post-test probability of 55, 30, and 20% respectively.
The clinical history in patients with unclassified arthritis can largely predict the presence of antibodies to B burgdorferi. The The presence of characteristic signs or symptoms of Lyme borreliosis in the clinical history and physical examination of patients with arthritis should guide rheumatologists in the decision to request a test for antibodies to B burgdorferi.
The purpose of this study was to investigate how we could estimate the presence of antibodies to B burgdorferi from clinical data in patients with arthritis, and how this influences the decision to prescribe antibiotic treatment.
Patients and methods Antibodies to B burgdorfferi were determined in all patients with arthritis from the outpatient department of rheumatology of the University Hospital of Leiden-that is, those patients in whom a firm rheumatic diagnosis could not be made on their first visit or after several visits. Specifically, these patients did not fulfil criteria for rheumatoid arthritis, osteoarthritis, gout, systemic lupus erythematosus, chondrocalcinosis, reactive arthritis, or seronegative spondyloarthropathy. Based only on the clinical history and physical examination of the individual patient, all patients were given a rank number from 1 to 4, where 1 is considered unlikely and 4 very likely to be Lyme arthritis. The criteria for these rank numbers were set for this particular study ( 30%/o (figure) .
Knees are the most affected joints in Lyme borreliosis.' 5 7 Therefore we placed all the patients with a first attack of arthritis of the knee and with recurrent arthritis of the knee in one group (41 patients from ranks 2 to 4). After this we calculated the sensitivity (14%), the specificity (95%), the positive predictive Post-test probability Post-test probability ofLyme arthritis at different cutoff levels in patients with unclassified arthritis after application oflikelihood ratios (pretest probability 9%/q). value (66%), and the likelihood ratio (3 0) (table 4) . This likelihood ratio was associated with a post-test probability of Lyme borreliosis of 20% (figure). As only nine of the 102 patients with unclassified arthritis had positive Lyme serology, the serological test can be regarded as unnecessary in 93 patients (91%). If antibodies to B burgdorferi had been determined in the 15 patients with rank numbers 3 and 4 only, the test would have been unnecessarily ordered in only nine patients. This implies that the number of requested tests for antibodies to B burgdorferi would be decreased from 102 to 15-that is, a decrease of 86%. This would have been at the expense of the three patients with rank numbers 1 and 2 who were also positive for antibodies to B burgdorferi (table 2) . These three patients are clinically believed to have a low probability of Lyme arthritis.
Antibodies to B burgdorferi were determined in 41 patients with arthritis of the knee; six were positive for these antibodies. Therefore the test was unnecessarily ordered in 35 patients (85%). Five of six patients with arthritis of the knee and positive for antibodies to B burgdorfieri were placed in ranks 3 and 4.
If requests for antibodies to B burgdorferi had been made for patients with arthritis of the knee with rank numbers 3 and 4, requests could have been decreased from 41 to five (88%) at the expense of one patient with rank number 2. 15 The clinical value of Western blotting, cell mediated immunity testing, urine antigen testing, and the polymerase chain reaction still have to be determined. In the meantime, it is up to the clinician to decide whether a post-test probability of a disease of, say, 50% is sufficiently supportive to start treatment in a patient with arthritis. If the clinical history in a patient with arthritis is likely to be Lyme borreliosis (in our study patients with rank numbers 3 and 4), the chances of having Lyme borreliosis are about 55%. This degree of suspicion is probably high enough to justify starting treatment with antibiotics in a patient with arthritis, especially because the first choice treatment with doxycycline by mouth is Clinical evidence should outweigh serological results. Therefore it would be realised that the three patients positive for antibodies to B burgdorferi who are clinically considered to have a low probability of Lyme arthritis (rank numbers 1 and 2) may in fact be asymptomatic. This would be the case if they have been infected by borrelia strains at some time in the past giving rise to the development of specific antibodies and if their arthritis was not due to Lyme borreliosis but to another (as yet unknown) cause. Asymptomatic infection with B burgdorferi (positive antibodies but no clinical disease) has been found in 3-20% of healthy subjects.6 16 The prevalence of asymptomatic infection correlates roughly with the degree of exposure.6 12 Secondly, if likelihood ratios are to be applied in clinical practice; the doctor must have a reasonable estimate of the probability for Lyme borreliosis in the patient. This implies that prevalence data should be available. Prevalence data for Lyme arthritis in patients with unclassified arthritis are available for two different parts of the Netherlands.3 These prevalence data can probably be extrapolated to other parts of the Netherlands. We feel that the calculated likelihood ratios can be transported to patients with unclassified arthritis in a setting comparable with ours. Thirdly, our intention was to point out that clinical findings should guide the decision to select a serological test. If the doctor is convinced that a patient with arthritis has Lyme arthritis, the patient should be treated appropriately, independently of the serological test result. Unfortunately, the clinical history and symptoms are not always clear and the doctor may feel that he or she needs more support for the diagnosis. We have tried to elucidate for which patients the serological Lyme test should be selected to improve the appropriateness and efficiency.
Discussion
In conclusion, in patients with unclassified arthritis clinical data are highly associated with the likelihood of a positive test for antibodies to B burgdorferi. Knowledge of the pretest probability of disease, extracting key elements from the patient's clinical history and the physical examination, and application of likelihood ratios can guide the decision to request tests for antibodies to B burgdorferi for these patients. Such 
